Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Malignant Mesothelioma Market Size Changed, over the years?

The market size for malignant mesothelioma has seen robust growth in the past few years. The projected growth from $2.46 billion in 2024 to $2.63 billion in 2025 indicates a compound annual growth rate (CAGR) of 6.8%. This growth during the historic period can be credited to factors like amplified investments in cancer research, an increase in lawsuits related to asbestos exposure, growth in hospital investments, a surge in the aging population, and the advancement in AI-based drug discovery platforms.

How Much Will the Malignant Mesothelioma Market Be Worth in 2029?

The market size of malignant mesothelioma is projected to experience substantial expansion in the upcoming years, swelling to $3.41 billion by 2029 with a compound annual growth rate (CAGR) of 6.7%. The predicted surge in the forecasted period is due to the increased adoption of immunotherapy treatments, a higher focus on individualized medicine, a rise in the use of less invasive surgical methods, enhanced health care spending, and an increase in clinical trials. Top trends during the forecast period are expected to be advancements in immunotherapy, bespoke medicine, initiatives for earlier detection, less invasive surgical procedures, and regulatory endorsements.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

Which is the Largest Company in the Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center

What Are the Main Market Drivers in the Malignant Mesothelioma Industry?

The upsurge in clinical studies and innovative attempts should fuel the expansion of the malignant mesothelioma market. Clinical studies and advancements focus on carrying out scientific research and experiments to formulate new medications, therapies, and medical apparatus. These endeavors encompass the evaluation of new products for safety, effectiveness, and potential adverse effects under closely monitored clinical trials. The escalation in clinical research and development can be attributed to the growing need for better and further developed therapeutic options, particularly due to increasing chronic diseases and complex conditions. Malignant mesothelioma is driven by research and development endeavours, speeding up progress in diagnosis, therapy, and targeted treatments, promoting innovative strategies to boost early detection, improving survival rates, and formulating more effective, less intrusive therapeutic options. For example, Anadolu Agency, a news agency based in Turkey, reported in January 2025 that clinical trials constitute nearly 40% of the U.S. pharmaceutical research budget, equating to roughly $7 billion per annum. As such, the ascending research and development endeavors are propelling the expansion of the malignant mesothelioma market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp

How Is the Malignant Mesothelioma Market Segments Structured?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

What Strategic Trends Are Transforming the Malignant Mesothelioma Market?

Key players in the malignant mesothelioma market are striving to develop improved treatment methods, such as monoclonal antibody therapies, to curb tumor growth and enhance the accuracy of treatment. These monoclonal antibodies are synthetic proteins created in labs that can emulate the immune system’s capability to identify and target distinct antigens, like those on cancer cells. For example, Ono Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, secured supplemental approval in Japan in November 2023 for the widened use of Opdivo (nivolumab), an anti-human PD-1 monoclonal antibody for malignant mesothelioma treatment (excluding malignant pleural mesothelioma). This approval indicates Opdivo’s potential as a fresh treatment option for this disease, where no standard treatments were formerly available. Opdivo has been recognized as an orphan drug for this usage, underscoring its potential to meet a significant medical necessity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Which Global Regions Offer the Highest Growth in the Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22046

This Report Delivers Insight On:

1. How big is the malignant mesothelioma market, and how is it changing globally?

2. Who are the major companies in the malignant mesothelioma market, and how are they performing?

3. What are the key opportunities and risks in the malignant mesothelioma market right now?

4. Which products or customer segments are growing the most in the malignant mesothelioma market?

5. What factors are helping or slowing down the growth of the malignant mesothelioma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model